Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Dynavax has experienced fluctuations in stock performance since the author's initial coverage. HEPLISAV-B is Dynavax's primary revenue source for the foreseeable future, with CpG-1018 currently sidelined. Supported by ample liquidity, Dynavax is evaluating business development on a disciplined basis.
How Much Upside is Left in Dynavax Technologies (DVAX)? Wall Street Analysts Think 135.98%
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 136% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Dynavax Technologies Corporation (DVAX) Q2 2024 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Cox - VP, Investor Relations & Corporate Communications Ryan Spencer - CEO Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - CFO Conference Call Participants Matthew Phipps - William Blair Phil Nadeau - TD Cowen Jon Miller - Evercore Paul Choi - Goldman Sachs Roy Buchanan - JMP Securities Operator Good day ladies and gentlemen and welcome to the Dynavax Technologies' Second Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Dynavax Technologies (DVAX) Tops Q2 Earnings Estimates
Dynavax Technologies (DVAX) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago.
Natixis Advisors L.P. Buys 1,804 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)
Natixis Advisors L.P. boosted its stake in Dynavax Technologies Co. (NASDAQ:DVAX – Free Report) by 10.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,058 shares of the biopharmaceutical company’s stock after purchasing an additional 1,804 shares during the quarter. Natixis Advisors L.P.’s holdings in Dynavax Technologies were worth $266,000 as of its most recent SEC filing. Other institutional investors and hedge funds have also added to or reduced their stakes in the company. DekaBank Deutsche Girozentrale bought a new stake in Dynavax Technologies in the third quarter valued at about $33,000. Advisor Resource Council bought a new stake in Dynavax Technologies in the fourth quarter valued at about $144,000. Rathbones Group PLC bought a new stake in Dynavax Technologies in the third quarter valued at about $158,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Dynavax Technologies in the fourth quarter worth about $209,000. Finally, AlphaMark Advisors LLC bought a new stake in shares of Dynavax Technologies in the fourth quarter worth about $230,000. Institutional investors own 96.96% of the company’s stock. Insider Transactions at Dynavax Technologies In other news, CAO Justin Burgess sold 20,526 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $12.78, for a total transaction of $262,322.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.98% of the stock is owned by insiders. Dynavax Technologies Stock Down 1.5 % DVAX stock opened at $11.11 on Monday. The company has a debt-to-equity ratio of 0.36, a current ratio of 15.20 and a quick ratio of 14.10. The stock has a market capitalization of $1.45 billion, a P/E ratio of 185.17 and a beta of 1.30. The business has a 50-day moving average of $11.81 and a 200-day moving average of $12.87. Dynavax Technologies Co. has a fifty-two week low of $10.48 and a fifty-two week high of $15.15. Wall Street Analyst Weigh In Several equities research analysts have issued reports on the company. The Goldman Sachs Group assumed coverage on Dynavax Technologies in a report on Thursday, February 1st. They issued a “neutral” rating and a $20.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $29.00 price target on shares of Dynavax Technologies in a report on Thursday, May 9th. StockNews.com downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Friday, April 26th. Finally, William Blair restated an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 23rd. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.33. Get Our Latest Report on DVAX About Dynavax Technologies (Free Report) Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
